BiotechTube
Rational Vaccines

Rational Vaccines

Boston, United States· Est.
rationalvaccines.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Rational Vaccines is a private, pre-revenue biotech firm founded in 2015, headquartered in Boston, USA, targeting the vast unmet medical need in herpes simplex virus infections. The company's core approach involves a proprietary platform for live-attenuated vaccine design, with its lead program focused on genital herpes. While primarily targeting HSV, the company has also indicated exploration of its technology for COVID-19, though its primary focus and stated goal is the eradication of herpes.

Infectious DiseaseDermatologySexual Health

Technology Platform

Proprietary platform for the rational design of live-attenuated viral immunotherapeutic and prophylactic vaccine candidates.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The global prevalence of HSV creates a multi-billion dollar market for a first-in-class vaccine, with significant unmet need for both prophylactic and therapeutic options.
Success in herpes could validate the live-attenuated platform for application against other persistent viral infections, creating substantial long-term value.

Risk Factors

High clinical risk due to the historical difficulty of developing effective herpes vaccines and specific safety concerns around live-attenuated HSV strains.
Financial risk is elevated as a pre-revenue company dependent on investor funding to advance costly clinical trials.
The CEO's non-traditional biopharma background may be perceived as an operational risk by some investors.

Competitive Landscape

The herpes vaccine space is competitive and challenging, with decades of failed attempts by major pharma. Current competitors include large firms like GSK and biotechs like BioNTech, employing subunit, mRNA, and other modalities. Rational Vaccines' live-attenuated approach is a distinct and higher-risk strategy that, if successful, could offer advantages in durability and strength of immune response.

More companies in Biologics / Biosimilars →More companies in United States →